Ticker

NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings presented at the Alzheimer's Association International Conference (AAIC®) 2026 in London. Following collaboration…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer's Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An…

More than 75% of LeqembiÂ-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEAD

LEQEMBIÂ Real-World LEADER Study Presented at AAICÂ 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable a

STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving Leqembi over an average of 17 months. The results were…